---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-029310"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:07:36.398489+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Reviva announces positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia

## Summary
- Primary endpoint met: brilaroxazine 50 mg showed 10.1-point PANSS reduction vs placebo (p<0.001) at week 4.
- Statistically significant improvements in all major symptom domains and secondary endpoints at 50 mg dose.
- Well-tolerated with no drug-related SAEs; discontinuation rates lower than placebo (16% vs 22%).
- Plans to report OLE topline data in Q4 2024 and initiate Phase 3 RECOVER-2 in Q1 2024; NDA submission expected 2025.

## SEC filing metadata
- accession: 0001437749-23-029310
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923029310/0001437749-23-029310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923029310/rvph20231029_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-029310
- JSON: https://secwatch.observer/filing/0001437749-23-029310.json
- Plain text: https://secwatch.observer/filing/0001437749-23-029310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.